Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients

International Journal of Clinical Oncology

Volumn 7, Issue 5, 2002, Pages 330-333

  Ishikawa, H ^a   Fujiwara, K ^a   Suzuki, S ^a   Tanaka, Y ^a   Kohno, I ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Ovarian cancer; Paclitaxel; Platelet sparing effect

Indexed keywords

CARBOPLATIN; PACLITAXEL; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; INFUSION; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0036808068     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200050     Document Type: Article

References (9)

1. Ozols RF, Bundy BN, Fowler J, et al. (1999) Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage epithelial ovarian cancer: A Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 18: abstract 1373
2. Du Bois A, Lueck HJ, Meier W, et al. (1999) Cisplatin/paclitaxel versus carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 18: abstract 1374
3. Belani CP, Kearns CM, Zuhowski EG, et al. (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations of combination paclitaxel and carboplatin in patients with metastatic non-small lung cancer. J Clin Oncol 17:676-684
4. Bookman MA, McGuire WP III, Kilpatrick D, et al. (1996) Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902
5. Fujiwara K, Yamauchi H, Suzuki S, et al. (2001) The plateletsparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 47:22-26
6. McGuire WP, Hoskins WJ, Brady ME et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334:1-6
7. Piccart MJ, Bertelsen K, James K, et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. J Natl Cancer Inst 92:699-708
8. Alberts DS (1999) Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26:8-14.
9. Pertussini E, Ratajczak J, Majka M, et al. (2001) Investigation of the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 97:638-644